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Abstract
Coronavirus Disease (COVID)-19 is a pandemic since March 11, 2020. The total case is more than a half million 
worldwide. Liver injury is quite common in COVID-19 patients. Direct viral infection is possible due to the presence of 
angiotensin converting enzyme 2 in cholangiocytes and hepatocytes. Other proposed mechanisms are virus-induced 
cytopathic effects, inflammation process, hypoxia and shock, increased apoptotic activity, increased positive end 
expiratory effect, and drug-induced. The manifestation of liver injury is mild and transient with elevated liver enzymes, 
bilirubin, and gamma-glutamyl transferase levels. Deterioration of liver function can occur in subjects with COVID-19 
and underlying liver injury. The management is principally supportive. Hepatoprotective drugs may be administered 
in severe cases.
Introduction
Pneumonia due to unknown etiology was 
found in Wuhan, Hubei Province, China in December 
2019 [1], [2], [3]. Huanan seafood market was 
suspected as the starting area of the spreading. A 
virus, namely, 2019 novel coronavirus (CoV) was 
identified as the etiology of the disease in January 7, 
2020. In February 11, 2020, International Committee on 
Taxonomy of Viruses renamed 2019 nCoV as severe 
acute respiratory syndrome-CoV-2 (SARS-CoV-2). 
Later, World Health Association (WHO) announced 
the disease caused by SARS-CoV-2 infection as CoV 
disease-(COVID-19) [1], [4]. In March 11, 2020, the WHO 
announced COVID-19 as a pandemic [3], [5], [6], [7].
CoV is an enveloped, single-stranded positive-
sense RNA virus [1], [7], [8]. Its Alpha and Beta generas 
commonly infect mammals while Gamma and Delta 
infect birds. SARS-CoV-2 itself is belonged to Beta-
CoV genus and Coronaviridae family [1], [5], [7], [9]. 
Previously, two CoVs had caused epidemics. The first 
was SARS-CoV in Guangdong, China in November 2002 
and the second was Middle East respiratory syndrome 
CoV (MERS-CoV) in Saudi Arabia in 2012 [1], [3], [10]. 
The first epidemic caused 774 deaths while the second 
caused 858 [1]. The mortality rate from SARS-CoV-2 is 
lower compared to SARS and MERS [9], [10].
Epidemiology
Median age of patients with COVID-19 is 
between 41 and 57 years. Male is dominant compared 
to female [1], [11]. Even though, there are several 
studies reporting comparable proportion of patients 
based on gender [2], [4]. About 25.2–50.5% patients 
have comorbidities such as hypertension, diabetes, 
chronic obstructive pulmonary disease, cardiovascular 
disease, and malignancy [1]. About 10.8% patients 
have pre-existing liver disease [12]. The mortality of 
COVID-19 ranges from 0% to 14.6% [1]. The most 
common death-leading complication is acute respiratory 
distress syndrome [10]. Factors contributing to higher 
risk of mortality are older age, underlying comorbidities, 
and disease severity based on clinical findings and 
auxiliary examinations [11], [13]. At the time of writing, 
there are 5,491,678 cases of COVID-19 with total 
deaths of 349,190 cases. The most prevalent region 
is America, followed by Europe [14]. The incidence of 
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liver injury due to COVID-19 was varied between 14.8% 
and 78% [3], [9]. Other literatures stated that liver injury 
is observed in 60% patients with COVID-19 [8], [15]. 
Cai et al. found a similar rate of liver injury which was 
76.3% of total patients with COVID-19 and 21.5% of all 
patients on admission [5].
Pathophysiology
Bats are the natural reservoir of SARS-CoV-2 
and the virus spreads to human through pangolins as 
one of the intermediate hosts [1]. The virus may be 
isolated from pangolins, especially Malayan pangolins. 
However, genomic sequence of SARS-CoV-2 in 
human is different from the wild virus, suggesting 
that mutation may have been occurred which allows 
human-to-human transmission [13]. Human-to-human 
transmission occurs through respiratory droplets 
directly or indirectly [4]. Fecal-oral transmission must 
also be wary of since viable SARS-CoV-2 can be 
isolated from patient’s fecal sample [16]. SARS-CoV-2 
infection is initiated by binding of spike glycoprotein to 
angiotensin converting enzyme 2 (ACE2). This process 
is followed by cell membrane fusion [11], [15], [17]. Viral 
RNA then integrates into host cell DNA. This process 
initiates viral protein synthesis and assembly of new 
viruses which readily infect other cells and damaging 
the cell [15], [18]. The affinity of SARS-CoV-2 to ACE2 
is stronger compared to SARS-CoV [12], [13].
Literatures stated that ACE2 is highly 
expressed in cholangiocytes but only slightly in 
hepatocytes. As we know that bile duct epithelial cells 
play an important role in liver regeneration and immune 
response, it raises possibility that SARS-CoV-2 may 
directly invade those cells and cause liver function 
dysregulation [15], [16], [19], [20]. Furthermore, virus-
induced cytopathic effects may directly cause liver 
damage [3]. Inflammation process, which is known 
as cytokine storm, also played an important role in 
damaging the liver of patients with critical condition due 
to COVID-19 [4], [6], [9], [11]. Lymphocytes are important 
in balancing immune response and preventing cytokine 
storm. Lymphopenia in COVID-19 patients leads to 
aggravation of inflammatory response. Lymphopenia 
and elevated C-reactive protein (CRP) level were 
associated with the severity of liver injury, confirming 
cytokine storm as one of the underlying mechanisms 
of liver injury [3], [11], [15]. Hypoxia and shock from 
COVID-19 may cause ischemia in body organs including 
liver. This is another hypothesized mechanism of liver 
injury in patients with COVID-19 [6], [11].
SARS-CoV-2 infection is also found to increase 
apoptotic activity of hepatocytes. The process is 
mediated by SARS-CoV-2-specific protein 7a through 
caspase-dependent pathway [9]. Increased positive end 
expiratory pressure may also cause hepatic congestion 
by increasing right atrial pressure and impending venous 
return [3], [15]. Drug-induced liver damage should also be 
put in mind since antiviruses and antibiotics may increase 
the workload of liver. Hydroxychloroquine is used as one 
of the treatment choices due to its effect in alleviating 
disease progression but, in the other hand, it may cause 
hepatic failure. In patients with underlying liver diseases, 
such as chronic hepatitis and non-alcoholic fatty liver, 
the above situation will surely even more impair the liver 
function [3], [4], [6], [9], [11], [15], [16], [17].
Clinical Manifestations
Clinical symptoms of COVID-19 range 
from mild to severe. A study reported that moderate 
clinical severity patients were dominant. Fever is the 
most common symptom, followed by cough, fatigue, 
myalgia, sputum production, and headache [1], [2], [3]. 
Gastrointestinal symptoms are quite common such as 
diarrheas, loss of appetite, nausea, and vomiting [1], [16]. 
Gastrointestinal symptoms are more frequent in SARS 
and MERS compared to COVID-19 [1].
Various degree of liver damage had been 
reported in COVID-19 patients marked by elevated 
total bilirubin, alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST) levels [19]. A 
study by Fan et al. showed that 37.2% patients with 
COVID-19 have abnormal liver function on admission 
and had higher fever compared to those with normal 
liver function [4]. Autopsy result of deceased patients 
showed that 58–78% of COVID-19 patients suffer from 
liver injury [16]. Higher prevalence of liver injury is 
observed in males, patients with more severe disease 
course, older age, and patient who received lopinavir/
ritonavir [4], [16]. The use of lopinavir/ritonavir increases 
the risk of liver injury as high as 4 times compared to 
patients who do not receive those antivirals [5]. The 
severity of liver injury is associated with the severity 
of disease course [9], [15], [17]. Table 1 summarizes 
evidence regarding liver injury in patients with COVID-19.
Table 1: Evidences of liver injury in patients with COVID-19
Authors Subjects Findings
Fan et al. [4] 148 37.2% subjects had abnormal liver function on admission
Patients with liver abnormality had higher fever, higher 
procalcitonin and CRP levels, and longer hospital stays
Cai et al. [5] 417 21.5% subjects had abnormal liver function during 
hospitalization
ALT, AST, total bilirubin, and GGT levels were elevated 
more than 3 times the upper normal limit within 2 weeks of 
hospitalization
Huang et al. [10] 41 31% subjects had abnormal liver function
Subjects admitted to ICU had higher AST level compared 
to non-ICU
Zhang et al. [21] 82 78% non-survivor subjects had hepatic injury
Huang et al. [22] 36 13.33% subjects had abnormal ALT, 58.06% had abnormal 
AST, and 12.9% had abnormal total bilirubin levels
Chen et al. [23] 99 28% subjects had elevated ALT, 35% had elevated AST, 
18% had elevated total bilirubin, and 98% had low albumin 
levels
CRP: C-reactive protein. ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, GGT: Gamma-
glutamyl transferase, ICU: Intensive care unit. COVID: Coronavirus disease.
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COVID-19 in Patients with Pre-existing 
Liver Disease
COVID-19 patients with liver injury tend to 
develop severe pneumonia and have longer hospital 
stay [4], [5], [24]. Literature stated that patients with 
hepatitis B or C viral infection are more prone to suffer 
from severe hepatitis due to enhanced viral replication 
during COVID-19 course. On the other hand, patients 
with pre-existing live diseases such as non-alcoholic 
fatty liver disease and liver cirrhosis had higher risk to 
develop severe form of COVID-19. Liver transplantation 
should be conducted prudently since the virus can be 
transmitted through transplanted organ [3]. Subjects 
with chronic liver disease coexisting with COVID-19 
tended to suffer from deterioration of liver disease. 
The deterioration was in line with increasing stage of 
liver disease, resulting in higher mortality in subjects 
with liver diseases compared to those without (hazard 
ratio 19.2) [25]. This finding is confirmed by a study 
by Iavarone et al. They reported that the presence of 
COVID-19 deteriorates liver function and increases the 
mortality of subjects with underlying liver injury. The 
30-day-mortality rate for subjects with COVID-19 and 
pre-existing liver cirrhosis was as high as 34%. The 
mortality was influenced by severity of liver disease [26].
Auxiliary Examinations
The most common laboratory findings are 
lymphopenia, thrombocytopenia, and leukopenia. Other 
inflammatory markers such as CRP and interleukin-6 
are also elevated [1]. Liver enzymes elevation is also 
observed [1], [3], [5], [9], [15], [16], [17]. ALT level rose 
in 16–35% patients while elevated AST was observed 
in 21% patients [19]. Feng et al. reported the elevation 
of AST level in 6.2–36.6% patients with COVID-19 and 
elevation of AST level in 21.3–28.1% patients [11]. 
Ridruejo and Soza found a lower rate of AST and ALT 
elevation which is between 16% and 35% [6]. Other 
markers for liver injury are also detected including 
elevated bilirubin level and decreased albumin level. 
Gamma-glutamyl transferase (GGT) might also be 
elevated [3], [5], [9], [15], [16], [17]. In the other hand, alkaline 
phosphatase did not raise significantly [4], [5], [11], [16], [19]. 
Chest computed tomography showed ground glass 
opacity, bilateral patchy shadows, and consolidation 
in subsegmental areas [1], [10], [27]. Reverse-
transcriptase polymerase chain reaction (RT-PCR) from 
nasopharyngeal swab is considered as gold standard 
for diagnosing COVID-19 [1]. Other specimens also 
showed positive result with bronchoalveolar lavage fluid 
held the highest positive rate (93%), followed by sputum 
(72%), nasal swabs (63%), fibrobronchoscope brush 
biopsy (46%), pharyngeal swab (32%), feces (29%), and 
blood (1%) [28].
From percutaneous liver biopsy specimen 
of COVID-19 patients with elevated ALT, there was 
marked apoptosis activity in the liver tissue, ballooning of 
hepatocytes, and mild-to-moderate lobular infiltration of 
lymphocytes. RT-PCR showed evidence of SARS-CoV-2 
genome in liver tissue but not in serum of patients [8], [9]. Viral 
particles could not been identified by electron microscopy 
or histopathology examination [3], [8], [15]. In contract, 
other literature reported that SARS-CoV-2 particles may 
be detected in liver tissue from autopsy of patients with 
COVID-19 [9]. Patients with underlying liver disease have 
higher risk of COVID-19 infection and poorer outcome [6]. 
Cirrhosis has higher risk of developing poorer outcome. 
As liver injury increases the risk of COVID-19 progression, 
the utilization of liver function tests may be used as 
predictor of disease outcome [5].
Management
The mainstay of COVID-19 management is 
supportive therapy. Antivirus (oseltamivir, lopinavir, 
remdesivir, and ritonavir), antibiotic, and antimalarial 
(chloroquine) are also administered but need further 
study regarding their efficacy [1]. Most liver damage in 
COVID-19 patients is mild and transient and may resolve 
without specific treatment. Supportive measures must be 
taken to fulfill pulmonary ventilation and prevent cytokine 
storm. Hepatoprotective drugs may be utilized in patients 
with pre-existing liver disease and in case of severely 
injured liver [11], [16], [17]. The development of vaccine 
is still under ongoing process and should be able in the 
next 12–18 months. Implementation of health protocol is 
important to contain the COVID-19 pandemic [24].
Conclusion
COVID-19 is an emerging pandemic which 
may cause liver injury. The presence of ACE2 in 
cholangiocytes and hepatocytes allows direct infection 
SARS-CoV-2 to liver. Other possible mechanisms are 
virus-induced cytopathic effects, inflammation process, 
hypoxia and shock, increased apoptotic activity, increased 
positive end expiratory effect, and drug-induced. Clinical 
manifestations are usually mild with elevated liver 
enzymes, bilirubin, and GGT levels. Albumin level may 
also decrease. Subjects with COVID-19 pre-existing 
liver injury tend to have deterioration of liver function 
and increased mortality. The management of liver injury 
in COVID-19 is supportive. Hepatoprotective drugs may 
be administered in severely injured liver.
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